Follicular lymphoma

It is a cancer of B cells — the white blood cells that normally make antibodies — and the NCI describes it as the most common slow-growing type of non-Hodgkin lymphoma.

“Indolent” is the word used in the literature, and it means slow-growing. It does not mean harmless, and it does not mean it will go away if left alone.

It usually affects people over 60, though it can develop at any age. In US registry data the median age at diagnosis is 64, which means half of people diagnosed are younger than that.

Because it grows slowly, it often causes few symptoms for a long time — which is why it is frequently found at an advanced stage, and why advanced stage means something different here than it does in a fast-growing cancer.

None of the sources we read for this page states a cause. We are treating that as unanswered rather than filling it in.

Nothing in these sources supports a lifestyle, diet, stress or exposure explanation, and we are not going to gesture at risk factors the sources do not carry.

The sources we read do not report on inheritance or family risk either. That is a gap in what we could verify rather than a reassurance.

For most people it behaves as a long-running condition rather than a short crisis. Lymphoma Action puts it plainly: most people live with follicular lymphoma for many years and are managed as though it were chronic.

It usually comes back. Periods of control are followed by relapse and a further line of treatment, and predicting when is genuinely difficult — not something being withheld.

It can change into a faster-growing lymphoma. The NCI reports a study in which 379 of 2,652 people — 14% — transformed to a more aggressive form after an initial diagnosis of follicular lymphoma, at a median follow-up of 6.8 years. If that happens, treatment changes entirely and follows the path used for the fast-growing lymphomas.

You may encounter the term POD24 online, and it is worth understanding before it frightens you. It stands for progression of disease within 24 months, and it describes a group whose lymphoma came back within two years of chemotherapy plus antibody treatment. It is a label applied after the fact, to a group, looking backwards. It is not a test anyone can take at diagnosis and it is not a prediction handed to you.

For many people the first plan is monitoring rather than treatment — regular check-ups, with treatment starting when the lymphoma causes symptoms. It is commonly done, and the reason is that starting earlier has not been shown to help while the side effects of treatment start immediately.

That is a real medical decision rather than a way of putting you off, and it is worth saying clearly because being told you have cancer and that nothing will be done about it today is one of the more disorienting things this library describes.

When treatment is needed, antibody therapy is central. Rituximab targets a protein called CD20 on the surface of B cells. It can be given on its own — Lymphoma Action notes a short four-week course in people without symptoms significantly delays the point at which more intensive treatment is needed — or combined with chemotherapy.

When the lymphoma is causing symptoms, chemotherapy is given together with rituximab or a related antibody, obinutuzumab. Antibody treatment may then continue as maintenance for up to two years.

If it transforms into a faster-growing lymphoma, it is treated as that lymphoma rather than as follicular lymphoma.

CAR T-cell therapy is available in later lines. Two products are approved in the European region from third or fourth line, and both are made from the patient’s own T cells.

The first thing many people go through is monitoring, and the psychological weight of it is routinely underestimated. Knowing you have a cancer that is being watched rather than treated is its own kind of difficult.

Living with it long term means scans, blood tests and clinic appointments continuing for years, alongside the knowledge that it will most likely come back at some point and that nobody can say when.

Treatment tends to come in episodes rather than as one course with an end date. People describe the rhythm of it — control, relapse, treat again — as something you learn rather than something you are told.

The possibility of transformation sits in the background for many people. It is worth knowing it exists and worth knowing it is not the common path.

Very little, and we want to be careful here rather than useful to ourselves.

The transplant that appears in follicular lymphoma is autologous — the person’s own stem cells, collected in advance, returned after high-dose chemotherapy. No donor, no registry, no match.

Even that is not a first-line treatment. EBMT’s 2025 recommendations say an autologous transplant is generally not recommended in first-line untransformed follicular lymphoma, and place it at relapse from second line onwards.

A donor transplant sits further out again: EBMT places it after an autologous transplant has already failed, and where CAR T-cell therapy is not available. That is a third-line-or-later position for a small minority of people.

CAR-T should not be mistaken for a donor treatment either. The approved products are made from the patient’s own T cells.

If you came here wondering whether you need to find a match, the honest answer for almost everyone reading this page is no.